Beta Blockers for Paroxysmal SVT Management

Acute Management Context

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend intravenous beta blockers as a reasonable option for acute episodes in hemodynamically stable patients, with a Class IIa recommendation 1, 3
• Beta blockers should only be attempted after vagal maneuvers and adenosine, which remain first-line acute therapies, according to the American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines 1
• Evidence supporting beta blockers for acute SVT termination is limited compared to diltiazem or verapamil, with one trial showing diltiazem superior to esmolol, as reported in Circulation 3

Ongoing/Chronic Management

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend oral beta blockers as a Class I option for long-term suppression of recurrent paroxysmal SVT in symptomatic patients without pre-excitation who are not candidates for or prefer not to undergo catheter ablation 1
• Oral beta blockers are effective in reducing frequency and duration of SVT episodes, according to the American College of Cardiology guidelines 1

Critical Safety Considerations

• Absolute contraindications to beta blockers include pre-excited atrial fibrillation or Wolff-Parkinson-White syndrome with AF/flutter, hemodynamic instability, signs of heart failure or pulmonary edema, second- or third-degree heart block or PR interval >0.24 seconds, and active asthma or reactive airways disease, as stated in the American College of Cardiology guidelines 1, 2

Treatment Algorithm

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend catheter ablation as the first-line definitive therapy for symptomatic paroxysmal SVT, with a single-procedure success rate of 94.3-98.5% and cure rates >90-95% 1, 2
• If ablation is declined or not a candidate, oral beta blockers, diltiazem, or verapamil are recommended as alternative options, according to the American College of Cardiology guidelines 1, 2

Clinical Nuances

• The choice between beta blockers and calcium channel blockers for chronic management should be guided by comorbidities, with beta blockers preferred when calcium channel blockers are contraindicated, such as in systolic heart failure, as recommended by the American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines 1, 2
• The most important clinical decision is whether to pursue catheter ablation versus chronic pharmacotherapy, with ablation offering definitive cure with minimal complications, according to the American College of Cardiology guidelines 2